Skip to content

Safety & Performance Randomized Study of the CiTop™ Guidewire for Peripheral CTO

A Feasibility, Multi Center Multinational Randomized Open Label Study, to Evaluate the Safety and Performance of the CiTop™ Guidewire for Crossing Total Occlusion in Peripheral Arteries.

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00482742
Enrollment
50
Registered
2007-06-05
Start date
2006-10-31
Completion date
2013-06-30
Last updated
2013-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheterization, Peripheral

Keywords

Chronic Total Occlusion

Brief summary

The main objectives of the study are: To evaluate the performance and safety of the CiTop guidewire, while attempting to cross thru total occlusions of various dimensions and morphology. To compare the safety and efficacy of the CiTop guidewire with standard guidewires in terms of impact on the treated artery. Following operation of the CiTop device, angiography demonstrated successful crossing of the occlusion with no visible evidence of arterial wall injury, dissection, or distal embolization. To assess ease of operation and the level of integration of the CiTop with standard interventional angiography procedure: Balloon angioplasty, placement of stent.

Interventions

Sponsors

Ovalum
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

Clinical Inclusion Criteria: * Patient with symptomatic peripheral vascular disease, intermittent claudication less than 30 meters, rest pain or tissue ischemia.(Fontain grade 3-4) * Critical limb Ischemia * The patient has Chronic Total Occlusion in limb arteries, aged at least 3 months. * Patient has chronic total occlusion (CTO) that is: * Documented angiographically, by the investigator or co-investigator. * CTO was defined as an obstruction of a main peripheral artery with no luminal continuity and with TIMI (Thrombolysis In Myocardial Infraction) flow grade of 0 or 1. * CTO location suitable for endovascular treatment (not in parallel location with the hip or knee joints). * Lesion ≤ 8cm in length * Lesion located in a segment with diameter more than 1.5 mm * Adequate compliance with follow-up and/or repeat angiography * No Contra-indication to treatment with aspirin or ticlopidine or clopidogrel and/or Heparin * Visible entry point of target lesion * NO cancer or other life threatening diseases or conditions * NO diagnosis or suspected renal failure (2 x ULN of creatinine) * Not suspected intolerance of the contrast agent * NO Drug abuse or alcoholism * Patients is NOT under custodial care * Women with childbearing potential are NOT pregnant (positive pregnancy test at the time of procedure).

Countries

Croatia, Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026